Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The aim of this study was to evaluate associations between vitamin D metabolites and antiretroviral therapy on BMD.

Multivariable linear regression models were constructed to evaluate the covariates of 1,25(OH)2D and BMD.

Who Took Part

According to the abstract, 160 individuals were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized and open-label study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the individuals and staff both knew the treatment.

Serum 25(OH)D and 1,25(OH)2D were measured in 160 individuals (90 receiving TDF-FTC, 70 receiving other NRTIs) at baseline from this study.

What Was Measured

Topics PubMed links to this paper include Anti-HIV Agents, Body Mass Index, Bone Density, Calcitriol, Dideoxynucleosides, Drug Combinations and Emtricitabine.

Author keywords: Antiretroviral therapy and Vitamin D.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc in 160 individuals.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.